NCT05139914View on ClinicalTrials.gov

Assessment of Dapagliflozin on Vascular Health in Patients With Type 2 Diabetes

PHASE4RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 31, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Diabetes Mellitus, Type 2Endothelial Dysfunction
Interventions
DRUG

Dapagliflozin

10 mg/day (in capsule form) of dapagliflozin for 6 weeks

OTHER

Placebo

Placebo capsule for 6 weeks

Trial Locations (1)

02118

RECRUITING

BU School of Medicine Evans 748, Boston

All Listed Sponsors
collaborator

American Heart Association

OTHER

lead

Boston University

OTHER

NCT05139914 - Assessment of Dapagliflozin on Vascular Health in Patients With Type 2 Diabetes | Biotech Hunter | Biotech Hunter